West Pharmaceutical Services (BSP:W2ST34) Current Accrued Expense: R$672 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:W2ST34 West Pharmaceutical Services Inc BSP:W2ST34
85 GF Score
Price R$50.44
GF Value R$52.58
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is West Pharmaceutical Services Current Accrued Expense?

West Pharmaceutical Services BSP:W2ST34 85 Current Accrued Expense is R$672 Mil as of Jun. 2026. GuruFocus rates BSP:W2ST34 with a GF Score™ of 85/100 and a GF Value™ of R$52.58 (Fairly Valued). The stock has 8 warning signs investors should review.

West Pharmaceutical Services's Current Accrued Expense for the quarter that ended in Jun. 2026 was R$672 Mil.

West Pharmaceutical Services's quarterly Current Accrued Expense declined from Dec. 2025 (R$1,057 Mil) to Mar. 2026 (R$623 Mil) but then increased from Mar. 2026 (R$623 Mil) to Jun. 2026 (R$672 Mil).

West Pharmaceutical Services's annual Current Accrued Expense declined from Dec. 2023 (R$666 Mil) to Dec. 2024 (R$650 Mil) but then increased from Dec. 2024 (R$650 Mil) to Dec. 2025 (R$1,057 Mil).

West Pharmaceutical Services Current Accrued Expense Related Terms

West Pharmaceutical Services Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for West Pharmaceutical Services's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

West Pharmaceutical Services Current Accrued Expense Chart

West Pharmaceutical Services Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 915.53 612.66 666.37 649.76 1,057.32

West Pharmaceutical Services Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 517.98 599.58 1,057.32 623.37 671.77
BSP:W2ST34
85GF Score
West Pharmaceutical Services Inc BSP:W2ST34
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

West Pharmaceutical Services Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of R$672 Mil mean?
West Pharmaceutical Services (BSP:W2ST34) has a Current Accrued Expense of R$672 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on West Pharmaceutical Services and its competitors.
Is West Pharmaceutical Services' Current Accrued Expense too high?
West Pharmaceutical Services' current Current Accrued Expense is R$672 Mil. Overall, West Pharmaceutical Services has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Current Accrued Expense compare to MDLN and SOLV?
West Pharmaceutical Services' Current Accrued Expense of R$672 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on West Pharmaceutical Services and its competitors. West Pharmaceutical Services's current Current Accrued Expense is R$672 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (BSP:W2ST34) is currently considered Fairly Valued. The stock's GF Value™ is R$52.58, compared to a current price of R$50.44 — trading 4.1% below its estimated fair value. The current Current Accrued Expense is R$672 Mil. West Pharmaceutical Services' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For West Pharmaceutical Services (BSP:W2ST34), the current Current Accrued Expense is R$672 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is West Pharmaceutical Services (BSP:W2ST34) Overvalued in 2026?

Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued. The current stock price of R$50.44 is trading 4.1% below its estimated GF Value™ of R$52.58. GuruFocus considers West Pharmaceutical Services to be Fairly Valued.

Key valuation signals for BSP:W2ST34:

  • Current Accrued Expense: R$672 Mil
  • GF Value™: R$52.58 vs. price of R$50.44 (4.1% below fair value)
  • GF Score™: 85/100 with 8 warning signs

No single metric tells the full story. See the BSP:W2ST34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

West Pharmaceutical Services Business Description

Address 530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
85GF Score

Get the complete analysis for BSP:W2ST34

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$50.44
Price
R$52.58
GF Value